195 related articles for article (PubMed ID: 15543082)
1. Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux.
Sikri V; Pal D; Jain R; Kalyani D; Mitra AK
Am J Ther; 2004; 11(6):433-42. PubMed ID: 15543082
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin.
Vadlapatla RK; Vadlapudi AD; Kwatra D; Pal D; Mitra AK
Int J Pharm; 2011 Nov; 420(1):26-33. PubMed ID: 21864659
[TBL] [Abstract][Full Text] [Related]
3. Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2.
Yamaguchi H; Yano I; Saito H; Inui K
Eur J Pharmacol; 2001 Nov; 431(3):297-303. PubMed ID: 11730721
[TBL] [Abstract][Full Text] [Related]
4. Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization.
Jain R; Majumdar S; Nashed Y; Pal D; Mitra AK
Mol Pharm; 2004; 1(4):290-9. PubMed ID: 15981588
[TBL] [Abstract][Full Text] [Related]
5. Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance.
Kwatra D; Vadlapatla RK; Vadlapudi AD; Pal D; Mitra AK
Int J Pharm; 2010 Aug; 395(1-2):114-21. PubMed ID: 20573570
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin.
de Lange EC; Marchand S; van den Berg D; van der Sandt IC; de Boer AG; Delon A; Bouquet S; Couet W
Eur J Pharm Sci; 2000 Dec; 12(2):85-93. PubMed ID: 11102735
[TBL] [Abstract][Full Text] [Related]
7. MDR- and CYP3A4-mediated drug-drug interactions.
Pal D; Mitra AK
J Neuroimmune Pharmacol; 2006 Sep; 1(3):323-39. PubMed ID: 18040809
[TBL] [Abstract][Full Text] [Related]
8. Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin.
Zhao YL; Cai SH; Wang L; Kitaichi K; Tatsumi Y; Nadai M; Yoshizumi H; Takagi K; Takagi K; Hasegawa T
Clin Exp Pharmacol Physiol; 2002 Mar; 29(3):167-72. PubMed ID: 11906478
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo.
Yamaguchi H; Yano I; Saito H; Inui K
J Pharmacol Exp Ther; 2002 Mar; 300(3):1063-9. PubMed ID: 11861816
[TBL] [Abstract][Full Text] [Related]
10. Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2.
Yamaguchi H; Yano I; Hashimoto Y; Inui KI
J Pharmacol Exp Ther; 2000 Oct; 295(1):360-6. PubMed ID: 10992002
[TBL] [Abstract][Full Text] [Related]
11. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
Dahan A; Sabit H; Amidon GL
AAPS J; 2009 Jun; 11(2):205-13. PubMed ID: 19319690
[TBL] [Abstract][Full Text] [Related]
12. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier.
Tamai I; Yamashita J; Kido Y; Ohnari A; Sai Y; Shima Y; Naruhashi K; Koizumi S; Tsuji A
J Pharmacol Exp Ther; 2000 Oct; 295(1):146-52. PubMed ID: 10991972
[TBL] [Abstract][Full Text] [Related]
13. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
[TBL] [Abstract][Full Text] [Related]
14. Binding characteristics of fluoroquinolones to synthetic levodopa melanin.
Ono C; Tanaka M
J Pharm Pharmacol; 2003 Aug; 55(8):1127-33. PubMed ID: 12956903
[TBL] [Abstract][Full Text] [Related]
15. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
16. Case Study 8: Status of the Structural Mass Action Kinetic Model of P-gp-Mediated Transport Through Confluent Cell Monolayers.
Bentz J; Ellens H
Methods Mol Biol; 2021; 2342():737-763. PubMed ID: 34272715
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.
Hughes J; Crowe A
J Pharmacol Sci; 2010; 113(4):315-24. PubMed ID: 20724802
[TBL] [Abstract][Full Text] [Related]
18. Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors.
Cormet-Boyaka E; Huneau JF; Mordrelle A; Boyaka PN; Carbon C; Rubinstein E; Tomé D
Antimicrob Agents Chemother; 1998 Oct; 42(10):2607-11. PubMed ID: 9756763
[TBL] [Abstract][Full Text] [Related]
19. Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells.
Lowes S; Simmons NL
Br J Pharmacol; 2002 Mar; 135(5):1263-75. PubMed ID: 11877335
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):787-93. PubMed ID: 12134948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
